Paulson Lorien M, Weaver Tyler S, Macarthur Carol J
Department of Otolaryngology, Oregon Health Sciences University, Portland, OR, United States.
Oregon Health Sciences University School of Medicine, Portland, OR, United States.
Int J Pediatr Otorhinolaryngol. 2014 Feb;78(2):223-6. doi: 10.1016/j.ijporl.2013.10.062. Epub 2013 Nov 21.
Tympanostomy tubes are commonly used for treatment of chronic otitis media with effusion (COME) or recurrent acute otitis media (RAOM) in patients with Down syndrome, but hearing outcomes in this population have been mixed, and complications appear to be common. We aim to characterize outcomes and complications associated with tympanostomy tube placement in this population.
Retrospective review. All patients with Down syndrome presenting to a tertiary academic pediatric otolaryngology practice over a ten year period from 2002 to 2012 who received tympanostomy tubes for COME, RAOM, or hearing loss were reviewed.
Long term follow up data was obtained in 102 patients, with average follow up 4.7 years. COME was the primary indication for tube placement in 100/102 (98%). Less than half of these patients (44%) initially failed their newborn hearing screen. Post operative hearing was found to be normal or near normal for the better hearing ear in 85/99 (85.9%), and normal to near normal in bilateral ears in 71/99 (71%). A majority (63.7%) of patients required two or more sets of tubes during the follow up period. Long term complications were common and were significantly increased if the patient required three or more sets of tubes, including chronic perforation (36.6% vs 8.2%, p<0.001), atelectasis (29.3% vs 1.6%, p<0.0001), and cholesteatoma (14.6% vs 0%, p=0.003).
COME is a frequent problem in Down syndrome, and the majority of patients will require two or more sets of tubes during their childhood and achieve normal postoperative hearing. Long term complications of otitis media appear to be more common in this population and appear to correlate with increasing number of tubes placed. More investigation is required to determine optimal treatment strategies for COME in patients with Down syndrome.
鼓膜置管常用于治疗唐氏综合征患者的慢性分泌性中耳炎(COME)或复发性急性中耳炎(RAOM),但该人群的听力结果不一,并发症似乎很常见。我们旨在描述该人群中鼓膜置管相关的结果和并发症。
回顾性研究。对2002年至2012年十年间在一家三级学术儿科耳鼻喉科就诊的所有因COME、RAOM或听力损失接受鼓膜置管的唐氏综合征患者进行回顾。
获得了102例患者的长期随访数据,平均随访4.7年。COME是100/102(98%)患者置管的主要指征。这些患者中不到一半(44%)最初新生儿听力筛查未通过。术后,99例患者中较好耳的听力正常或接近正常的有85例(85.9%),双耳听力正常至接近正常的有71例(71%)。大多数(63.7%)患者在随访期间需要两组或更多组的管子。长期并发症很常见,如果患者需要三组或更多组的管子,并发症会显著增加,包括慢性穿孔(36.6%对8.2%,p<0.001)、肺不张(29.3%对1.6%,p<0.0001)和胆脂瘤(14.6%对0%,p=0.003)。
COME在唐氏综合征中是一个常见问题,大多数患者在童年期间需要两组或更多组的管子,并能获得正常的术后听力。中耳炎的长期并发症在该人群中似乎更常见,并且似乎与置管数量的增加相关。需要更多的研究来确定唐氏综合征患者COME的最佳治疗策略。